Local production and downstream metabolism of specialized proresolving lipid mediators (SPMs) are pivotal in regulating their biological actions during resolution of inflammation. Resolvin D4 (RvD4: 4S,5R,17S-trihydroxydocosa-6E,8E,10Z,13Z,15E,19Z hexaenoic acid) is one of the more recently elucidated SPMs with complete stereochemistry biosynthesized from docosahexaenoic acid. Here, we report a new multimilligram commercial synthesis that afforded enough material for matching, validation, and further evaluation of RvD4 functions. Using LC-MS-MS profiling, RvD4 was identified at bioactive amounts in human (1 pg/mL) and mouse bone marrow (12 pg/femur and tibia). In mouse bone marrow, ischemia increased the formation of RvD4 > 37-fold (455 pg/femur and tibia). Two separate mouse ischemic injury models were used, where RvD4 reduced second organ reperfusion lung injury > 50%, demonstrating organ protection. Structurefunction relationships of RvD4 demonstrated > 40% increase in neutrophil and monocyte phagocytic function in human whole blood in comparison with 2 separate trans-containing double bond isomers that were inactive. These 2 isomers were prepared by organic synthesis: 4S,5R,17S-trihydroxydocosa-6E,8E,10E,13Z,15E,19Z-hexaenoic acid (10-trans-RvD4), a natural isomer, and 4S,5R,17S-trihydroxydocosa-6E,8E,10E,13E,15E,19Z-hexaenoic acid (10,13-trans-RvD4), a rogue isomer. Compared to leukotriene B 4 , D-series resolvins (RvD1, RvD2, RvD3, RvD4, or RvD5) did not stimulate human neutrophil chemotaxis monitored via real-time microfluidics chambers. A novel 17-oxo-containing-RvD4 product of eicosanoid oxidoreductase was identified with human bone marrow cells. Comparison of 17-oxo-RvD4 to RvD4 demonstrated that with human leukocytes 17-oxo-RvD4 was inactive. Together, these provide commercial-scale synthesis that permitted a second independent validation of RvD4 complete stereochemical structure as well as evidence for RvD4 regulation in tissues and its stereoselective phagocyte responses.
INTRODUCTION
Several new families of lipid mediators (LMs) derived from polyunsaturated fatty acids termed specialized proresolving mediators (SPMs) have recently been described for their importance in signaling endogenous programs in the resolution of inflammation and clearance of infection. 1 D-series resolvins are a subset of SPMs derived from docosahexaenoic acid (DHA) that have potent anti-inflammatory and proresolving actions. 1, 2 The acute inflammatory response is host protective, ideally self-limited, and follows an elaborate orchestration of neutrophilic recruitment to the site of injury, and its resolution, which involves cessation of neutrophil influx and macrophage-mediated clearance of cellular debris and bacteria. 3, 4 Resolvins are agonists acting at picomolar to nanomolar potency to dampen as well as counterregulate the initiators of this response (such as prostaglandins, cytokines, and chemokines) allowing for recovery with shortened resolution intervals to terminate the acute response. 1, 4 The importance of understanding and improving therapies to target endogenous resolution programs of inflammation is of interest for preventative care as well as treatment of chronic inflammation that can lead to a variety of serious illnesses and pathologies. 5, 6 Importantly, agonists acting on these new resolution pathways could potentially resolve inflammation without common unwanted side effects associated with nonsteroidal anti-inflammatory therapeutics. 7, 8 The essential role of proresolving mediators such as the D-series resolvins in infection and inflammation is further supported by the local mobilization of their precursor, DHA, at the site of injury during the cellular response to organ protection and repair. [9] [10] [11] During the acute inflammatory response, SPMs demonstrate several unique temporal and spatial profiles, being produced subsequent to the classical eicosanoids (i.e., prostaglandins and leukotrienes) that trigger proinflammatory cytokines and leukocyte recruitment. 12 Resolvins possess both anti-inflammatory and proresolving functions 1 based on their endogenous levels and release profile in response to tissue activation and damage. 5, 13 Downstream further metabolism can regulate the local function of resolvins during inflammation and infection. 14, 15 The local inflammatory response during ischemia is an area of interest as it is directly related to the acute and chronic inflammatory response observed following surgery (e.g., amputations or arterial bypass). 16 A better understanding of the acute inflammation that follows surgery and local ischemia is critical for developing more effective treatment strategies. For example, as physiologic stop signals for neutrophil influx, resolvins, such as RvD2, dampen proinflammatory responses, protecting organs from leukocyte-mediated collateral tissue damage and also by promoting tissue repair. 17, 18 Hind limb ischemia and reperfusion injury in mice are useful models of patients with arterial diseases 19 and second organ reflow injuries. 19, 20 Local production of potent SPMs at the site of injury is key for their broadacting roles and unique actions on human leukocyte trafficking during the initiation and resolution of acute inflammation in mice. 21 The D-series resolvin substrate, DHA, is enriched in the brain postcerebral ischemia during the inflammatory response and accumulates in the ischemic area postsurgical survival. 22 The biosynthesis of D-series resolvins involves metabolic conversion of DHA to monohydroperoxy precursors, which then undergo enzymatic conversion into specific resolvins. 23 Resolvin D4 (RvD4: 4S,5R,17S-trihydroxydocosa-6E,8E,10Z,13Z,15E,19Z hexaenoic acid) was first identified in selflimited mouse exudates and human leukocytes, 23 and its complete stereochemistry was recently established. 24 RvD4 is present in skin infections and, upon completion of the first total synthesis, was found to play an active role in host protection during bacterial pathogenesis in the skin. 24 As with all endogenous chemical mediators, it is critical to validate and confirm the structures and actions of new proresolving mediators using materials prepared by total organic synthesis. Progress on the actions of resolvins is hampered by the cost of long and complex synthetic routes. Hence, in this report we describe a completely new total organic synthesis for larger-scale commercial production of RvD4, that also permitted further confirmation and validation of the RvD4 complete stereochemical structure as well as its potent stereoselective functions. We used 2 separate in vivo mouse models of ischemic injury to assess RvD4, that is ischemic bone 19 and second organ reperfusion (e.g., reflow) injury of the lung. 20 The biosynthesis of RvD4 was significantly increased in ischemic bone marrow and also proved to be organ protective in the reperfusion injury model. To explore the structurefunction relationships and potential further local metabolism of RvD4, we also report herein the activity of RvD4 with direct comparison to other D-series resolvins (RvD1 to RvD5) and related RvD4 geometric isomers. Moreover, we report herein that RvD4 is enzymatically converted to a new 17-oxo-RvD4 metabolite, which displayed diminished bioactions compared to RvD4.
MATERIALS AND METHODS

Chemical confirmation of synthetic RvD4 and isomers
The proton chemical shift and coupling constants for the prepared 
Surgical induction of HLI
The surgical HLI protocol was performed as in Ref. 17 . Briefly, the second ischemia model employed C57BL/6J mice that were anesthetized with 2% isoflurane (with 2 L/min O 2 ) and maintained on a temperaturecontrolled water blanket at 37 • C (protocol no. 2016N000131). Hair was removed from the limb with depilatory cream followed by successive betadine and 70% ethanol washes to sterilize the incision area. A small incision was made lateral to the abdomen and superficial to the inguinal ligament exposing the inguinal fat pad. The overlying adipose tissue was set aside from the peritoneal lining, and a small tissue retractor was inserted to reveal the proximal femoral artery at its branching from the internal iliac artery. The membrane sheath surrounding the femoral artery and vein was then removed, and using ring forceps both vessels were gently grasped and raised so that 2 ligatures could be passed underneath them. The ligatures were then positioned roughly 2 mm apart and tightened to occlude blood flow. Both vessels were transected between the ligatures, the adipose tissue was repositioned, and the incision was closed with n-butyl-ester cyanoacrylate.
For sham-operated mice, an incision was made, the tissue was dissected to expose the vessels, and ligatures were passed under the vessels but not tied and no flow was occluded. Buprenorphine (0.5 mg/kg) was given immediately prior to surgery and again within 24 h postsurgery. Mice were euthanatized and marrow from the femur, and tibia of each ischemic limb was flushed with 1 mL cold methanol before solid phase extraction with internal standards (vide infra) and targeted LC-MS-MS. 
LM-SPM metabololipidomics
Flow cytometry
Human neutrophil isolation and macrophage differentiation
Human macrophage phagocytosis
Real-time neutrophil chemotaxis
Human neutrophils were isolated from peripheral whole blood collected from healthy volunteers using a Ficoll-Histopaque density gra- 
Incubations of RvD4 and recombinant enzyme
Enzymatic conversion of RvD4 (1 g) was carried out by suspending RvD4 in Tris-HCl buffer (pH 9.0). Next, ∼10 mM of NAD + (Sigma, St.
Louis, MO, USA) was added followed by addition of eicosanoid oxidoreductase (EOR), that is 15-hydroxy prostaglandin dehydrogenase (human recombinant, 5 g; Cayman Chemicals, Ann Arbor, MI, USA) and incubated at 37 • C for 2 h. 28 The reaction mixtures were stopped with cold methanol (30-60 min), followed by centrifugation, extraction, and subject to LC-MS-MS.
Statistics
Statistical analysis was performed using nonparametric tests including Student's t test for 2-group comparisons and 1-way analysis of variance (ANOVA) for multiple group comparisons with post hoc analysis using Tukey's or ANOVA with Bonferroni Multiple Comparison Test (more than 2 groups) using Prism version 6 (GraphPad, La Jolla, CA USA). P < 0.05 was considered significant.
RESULTS
A new total organic synthesis of RvD4
Given the pico-to nanomolar potency of resolvins, 1, 4 to obtain commercial quantities of RvD4 ( Fig. 1) and related isomers for further in vivo and in vitro studies, a multimilligram total organic synthesis was carried out first by building the C1-C9 fragment in 9 steps from Dribose (Fig. 1A) . The extent of the bioactions of RvD4 during inflammation and resolution hinges on the local biosynthesis and regulation. 
Human bone marrow RvD4: matching and endogenous production
To determine whether RvD4 is present in human tissue, we carried out metabolomics profiling on healthy human bone marrow and found Fig. 3D inset) , which clearly demonstrated that RvD4 was present in human bone marrow.
Endogenous RvD4 is produced in mouse bone marrow in response to ischemic injury
To investigate RvD4 production in response to acute sterile injury, mice underwent HLI by permanent femoral artery ligation and the production of RvD4 was monitored by targeted LC-MS-MS (Fig. 4) . This analysis revealed that RvD4 was present in mouse bone marrow and statistically significantly increased 1 day after HLI (455 ± 170 pg/femur and tibia), compared with sham-operated animals (12.4 ± 3.5 pg) (Fig. 4A) . The levels of RvD4 sharply declined by 5 days post-HLI (9.7 ± 1.8 pg), demonstrating a temporal regulation of RvD4. A representative MS-MS spectrum of RvD4 from mouse bone marrow is shown in Fig. 4B , with diagnostic ions used for identification. In addition to RvD4, we also identified its biosynthetic partner, 23 namely RvD3 (16.8 ± 4.7 pg/femur and tibia). Like RvD4, RvD3 was present in bone marrow of sham-operated mice and increased in a temporal manner during HLI (Fig. 4C) . We noted that levels of RvD4 at day 1 post-HLI were more than 28-fold greater than that of RvD3.
RvD4 protective actions in second organ lung injury
Since RvD4 was increased with local tissue ischemia in bone marrow (Fig. 4) , we next tested RvD4 in ischemia reperfusion (reflow) injury of the lung in mice. With enough RvD4 from the commercial-scale synthesis to carry out in vivo studies ( Figs. 1 and 2) , we assessed the impact of RvD4 in second organ ischemic reperfusion injury using pharmacological doses in this model of leukocyte-mediated tissue injury (Fig. 5 ). This is a separate in vivo mouse model of ischemia followed by second organ injury, also known as remote organ injury, where vaso-occlusion of the limb activates leukocytes locally. Next, when the vaso-occlusion is released by removing the tourniquet, neutrophils perfuse the lung and evoke collateral tissue damage. 9, 20 This system models the lung injury obtained in limb surgery. In these experiments, RvD4 was administered intravenously 50 min postischemia and 10 min before reperfusion injury (Fig. 5A ). Mice were euthanized 2 h after reperfusion, and second organ reperfusion lung injury was assessed by myeloperoxidase (MPO) to determine PMN infiltration. RvD4 (500 ng/mouse, i.v.) reduced lung PMN infiltration with MPO levels by ∼50% when directly compared to values obtained from control lungs with ischemic reperfusion alone (Fig. 5B) . RvD4 was also directly compared to the protective actions of RvD3, which was found earlier to be organ protective and proresolving. 21, 32 Histology samples of the second organ lung injury showed reduced infiltration of neutrophils into the lung by both RvD4 (not shown) and its comparator RvD3 and biosynthetic counterpart. Next, using state-of-the-art mass spectrometry based metabololipidomics, LMs were identified using MRM via direct comparison with synthetic and authentic standards.
Administration of RvD4 statistically significantly reduced the levels of proinflammatory eicosanoids: LTB 4 (60%), thromboxane (60%), prostaglandin E 2 (55%), and prostaglandin F 2 (52%) in the lungs of mice compared to untreated I/R mice ( Fig. 5C and D 
RvD4 structure function relationship with synthetic isomers in human whole blood
To assess the stereoselectivity of RvD4 actions, we prepared structurally related isomers. To obtain synthetic double bond isomers of RvD4 for biological evaluation, 1 mg of RvD4 was treated with 1 M LiOH in 4 mL of DME until the pH was 9-10 (see Supplementary Data for details). Next, 0.04 mg of glutathione (mg/mL in water) was added and the reactions were monitored by HPLC. 33 The 10-trans-RvD4
(10E-RvD4) eluted first with T R = 16.78 min followed closely by the F I G U R E 7 RvD4 stimulates phagocytosis of E. coli by human macrophages: toxin sensitivity. Human macrophages were treated with PTX or CTX, each at a concentration of 1 g/mL. RvD4 (1 nM) or vehicle was incubated with cells for 15 min at 37 • C, followed by addition of BacLight Green-labeled E. coli (2.5 × 10 6 CFU) for 60 min at 37 • C. Phagocytosis was determined using a fluorescent plate reader. Results are expressed as percent increase above vehicle control (E. coli alone); mean ± SEM from 6 individual donors. **P < 0.01, 2-tailed paired t test 10,13-trans-RvD4 isomer that eluted at T R = 17.67 min. The RvD4 starting material was essentially completely converted, as the RvD4 peak was not observed at T R = 18.45 min via LC-MS-MS. The pH was maintained at 9 throughout the course of the reaction. After 26 h, the pH was adjusted to pH 5 using 3.5 M AcOH. The product was purified by HPLC to afford ∼0.1 mg of 10E-RvD4 (Fig. 6A ), which gave a UV absorbance with max MeOH 262, 272, 281 nm and a band shoulder at 235 nm, and 0.05 mg of 10E,13E-RvD4 (Fig. 6A) , max MeOH 262, 272, 281 nm with a shoulder at 232 nm (Supplemental Fig. 3 ). These isomers ( Fig. 6A ) now permitted the assessment of the role of the double bond geometry (indicated by arrows in Fig. 6A ). The 10E-isomer of RvD4 is a natural isomer formed in biosynthesis of RvD4 and by isomerization during workup. 23 The 10E,13E-RvD4 isomer is thought to be a rogue molecule used here to assess the contribution of the 13,14-double bond in the cis configuration in native RvD4.
Since RvD4 gave protective actions in leukocyte-mediated second organ injuries of the lung (Fig. 5) , we next investigated the actions in key host defense mechanisms and resolution, namely human leukocyte phagocytosis by RvD4 and its isomers to explore structure function activity. In peripheral blood leukocyte phagocytosis, native RvD4 (4S,5R,17S-trihydroxydocosa-6E,8E,10Z,13Z,15E,19Z hexaenoic acid) increased E. coli phagocytosis greater than 50% in CD16 + (neutrophils)
as well as CD14 + (monocytes) compared to phagocytosis in the vehicle control as monitored by flow cytometry (Fig. 6C,D) . Enhancing phagocytosis of bacteria is a key action of resolvins and other proresolving mediators that promote killing and clearance. 34 More importantly, the 10E-RvD4 (10-trans-RvD4; 4S,5R,17S-trihydroxydocosa-6E,8E,10E,13Z,15E,19Z-hexaenoic acid), a natural isomer of RvD4 produced on its biosynthesis, 23 and 10E,13E-RvD4 (10,13-trans-RvD4; 4S,5R,17S-trihydroxydocosa-6E,8E,10E,13E,15E,19Z-hexaenoic acid), an unnatural isomer, did not significantly increase E.
coli phagocytosis by peripheral blood phagocytes above that of vehicle alone ( Fig. 6A-D ). These results demonstrate the critical role of the specific double bond geometry and stereochemistry of RvD4 ( Fig. 6A; highlighted in yellow) required for biological processes, namely neutrophil and monocyte phagocytosis of E. coli in human peripheral blood. Also of note, the actions of RvD4 in phagocytosis with human leukocytes proved to be CTX-sensitive and not PTX-sensitive (Fig. 7), suggesting a role for G s protein and G protein-coupled receptors in RvD4-mediated actions.
Enzymatic conversion of RvD4 by EOR and human bone marrow
Resolvins can undergo local inactivation via further metabolism. 15 We next assessed the impact of metabolic conversion via EOR to understand its role and structure of products in metabolism of RvD4. Incubating RvD4 in the presence of NAD+ (10 mM) at 37 • C with EOR (0.5 g) produced 17-oxo-RvD4 (Fig. 8A) . The structure of 17-oxoRvD4 and percent conversion by EOR (> 99%) were determined using reverse phase HPLC analysis and targeted LC-MS-MS. We found that the 17-oxo-RvD4 (R T = 11.88) had an earlier retention time to that of RvD4 (R T = 12.30) (Fig. 8B, D) and were isolated. Monitoring 17-oxoRvD4 with LC-MS-MS at m/z 373 = >101 yielded 6 diagnostic daughter ions, including m/z 241 that further confirmed the conversion to the 17-oxo-containing further metabolite and structure of 17-oxo-RvD4 (Fig. 8C,E) .
With this new information on the physical properties and formation of 17-oxo-RvD4, we next determined if RvD4 further metabolites are present in human tissue. Results in Fig. 9 document that human bone marrow leukocytes, when incubated with RvD4, produced 2 further products, namely 17-oxo-RvD4 and 15,16-dihydro-RvD4, that were identified by their MS-MS and ion fragments (Fig. 9 insets) .
Chemotaxis and phagocytosis with human leukocytes: comparisons of RvD4 and related structures
Given that 17-oxo-RvD4 is produced in human tissue, we next determined its actions compared to RvD4 (Fig. 10) . Directly compared to LTB 4 , none of the D-series resolvins stimulated neutrophil chemotaxis (Fig. 10A) . These results are consistent with those reported earlier using different microfluidic chambers with human PMN exposed (Fig. 10B ).
Since RvD4 stimulates phagocytosis, 24 we directly compared the 17-oxo-RvD4 to RvD4 in leukocyte phagocytosis (neutrophils and monocytes) of E coli in human peripheral blood and with human macrophages using real-time imaging (Fig. 10C, D) . In both 
DISCUSSION
In the present report, we document a new total organic synthesis RvD4 and its naturally occurring biosynthetic geometric isomers. 23, 35 In human whole blood RvD4 enhanced E. coli phagocytosis, a proresolving response by both CD14+ classical monocytes and CD16+ (Fig. 9 ) in blood cells and bone marrow.
In comparison, RvD1 is also rapidly metabolized by recombinant 15-PGDH/EOR, reaching maximal conversion within 20 min as measured by NADH levels. 28 It is likely that EOR conversion of RvD4 shares similar kinetics. Along these lines, it is noted in the present study that in mouse bone marrows following ischemic injury, RvD4 levels were the highest at Day 1 (455 ± 170 pg/femur and tibia), followed by a decline at Days 5-10 (Fig. 4) . It is possible that bone marrow leukocytes contain EOR that rapidly metabolized RvD4, contributing to the sharply reduced levels of RvD4 in Days 5 and 10. In comparison, in the ischemia-initiated second organ injury, RvD4 levels were 51.3 ± 18.5 pg/100 mg lung tissue 2 h following reperfusion (n = 4). Since 15-PGDH/EOR is highly expressed in lungs, 28 it is likely that RvD4 was also rapidly converted by EOR in lungs. It remains of interest to determine whether RvD3 is a substrate for EOR.
We found 17-oxo-RvD4 inactive at enhancing phagocytosis of E.
coli by human neutrophils, monocytes, and macrophages compared to its metabolic precursor RvD4 (Fig. 10) . These findings were similar to those with RvD1: As documented earlier, 17-oxo-RvD1 is the primary inactivation site, while the related 8-oxo-RvD1 metabolite remained active. 28 For comparison, another resolvin, RvD2, is converted to both 7-oxo-RvD2 and 16-oxo-RvD2 in adipose tissues, with 7-oxo-RvD2 being the major metabolic route that remains active on adipose-directed actions, whereas 16-oxo-RvD2 proves inactive. 37 A limitation of the present experiments is that future studies are needed to interrogate fully the biological relevance of this newly identified metabolic route of RvD4 conversion to the 17-oxo-containing metabolite and its potential inactivation in other human cell types and tissues. Our main goal in these experiments was to address and further establish the complete structure of RvD4, 23, 24 its scale-up synthesis, and the confirmation and rigorous validation of stereochemical selectivity in RvD4 functional responses. Also, these results provide evidence for a likely G protein-coupled receptor(s) that evokes intracellular signaling in response to RvD4, the identity of which remains to be determined.
In summation, the present findings reported herein demonstrate a new larger-scale total organic synthesis of RvD4 as well as document the proresolving and organ-protective actions of RvD4 in secondorgan reflow injury of the lung. We also identified endogenous production of RvD4 in both human and mouse bone marrow that was increased following ischemia. In addition, RvD4's structure-function activity was determined for the regulation of leukocyte responses. 
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